Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (October 2019)
39 slides from Windtree Therapeutics's investor presentation, Oct 25, 2019
Slide 1: Windtree Therapeutics, Inc. Corporate Presentation
Windtree Therapeutics, Inc. Corporate Presentation October 2019 WINDTREE THERAPEUTICS OTCQB: WINT
Slide 2: Forward-looking Statements
Forward-looking Statements To the extent that statements in this presentation are not strictly historical, including statements about the Company's clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agree
Slide 3: Windtree Investment Highlights
Windtree Investment Highlights = Late-stage pipeline of novel cardiovascular and pulmonary programs * Three phase 2 clinical programs and additional pre-clinical pipeline candidates in both cardiovascular and pulmonary indications = Lead cardiovascular program, istaroxime (ista), is a first-in-class
Slide 4: Windtree Therapeutics Portfolio
Windtree Therapeutics Portfolio Late Stage Programs in Cardiovascular and Acute Pulmonary Cardiovascular Istaroxime for the Treatment of Acute Heart Failure + Pre-Clinical Oral, Heart Foilure Candidates and Programs: cv-ist2 SERCA2a (Next Generation Dual (Selective Action) Action SERCA2a) Oral & iv.
Slide 5: Strategy for Value Creation
Strategy for Value Creation Planned Milestones + Three late-stage programs focused on significant markets with unmet needs + Multiple clinical and business milestones which have the potential to be catalysts Highly-experienced management team conducting smart, rigorous execution and leveraging oppor
Slide 6: Istaroxime
Istaroxime Dual Mechanism, SERCA2a Activator for the Treatment of Acute Heart Failure @ and Early Cardiogenic Shock S@ winotree a6
Slide 7: Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need
Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need = 6 million patients in the U.S. and over 18 million worldwide. The prevalence of HF is on the rise as is mortality = #1 cause of hospitalizations in patients over 65 years old in the United States and Western Europe w
Slide 8: Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need
Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need = Despite the need, there have not been meaningful new therapeutic advancements in acute heart failure for decades = Current approaches to improve acute cardiac dysfunction are associated with unwanted effects: *
Slide 9: Cardiac Output, Blood Pressure and Renal Function are Critical
Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF Patients and Their Outcomes Early drop in systolic blood pressure ‘and worsening renal function in acute heart In-Hospital Mortality Rates by Admission upper vegier Meenas am Systolic Blood Pressure Deciles (n = 4
Slide 10: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy ™ Novel intravenous agent designed to improve systolic contraction and diastolic relaxation and fill function of the heart = Unique, dual mechanism of effect that has been shown to impact both systolic and diastolic dysfunction © Inhibition of the sodium-pot
Slide 11: Istaroxime Phase 2a (HORIZON-HF) Study
Istaroxime Phase 2a (HORIZON-HF) Study = Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% * SBP 90-150 mmHg = N=120 (30/group) * Significant improvement in PC
Slide 12: Istaroxime Phase 2b Study Design and Measures
Istaroxime Phase 2b Study Design and Measures = After a positive phase 2a trial, the predecessor company conducted a phase 2b trial that was multicenter, double blind, placebo-controlled, parallel group = Hospitalized for recurrent AHF (dyspnea plus need for IV furosemide 240 mg); adult population *
Slide 13: Primary Endpoint — Significant Changes in E/e' Ratio
Primary Endpoint — Significant Changes in E/e' Ratio istaroxime 0.5 yg/kg/min vs. placebo istaroxime 1.0 yg/kg/min vs. placebo 20 20 10 00 10 5.20 “30 50 60 _ Infusion period no Infusion period Baseline 6hours 24hours 48 hours Baseline 6hours 24hours 48 hours @ Placebo - Cohort 1 —@-Istaroxime 0.5 y
Slide 14: Substantial Change in Stroke Volume Index
Substantial Change in Stroke Volume Index 80 70 60 50 40 30 20 10 VI (mi/beat/m?) 0.0 “10 20 istaroxime 0.5 yg/kg/min vs. placebo ‘SV (mlbeat/in?) 80 70 60 50 40 30 20 10 00 istaroxime 1.0 pg/kg/min vs. placebo ] Infusion period “1.0 20 ——— Infusion period Baseline hours 24hours 48 hours =@~ Placebo
Slide 15: Systolic Blood Pressure Maintained or Increased During Treatment
Systolic Blood Pressure Maintained or Increased During Treatment istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 yg/kg/min vs. placebo mo Be = = —* £* 3 an B B s £0 & | Ss Es Es 2 2 G4 os 2 ~@> Placebo - Cohort 1 -@= Istaroxime 0.5 yg/Kg/min Placebo - Cohort 2 ~@=Istaroxime 1.0 ug/Kg/min * prval
Slide 16: eGFR Maintained or Improved with Istaroxime
eGFR Maintained or Improved with Istaroxime istaroxime 0.5 wg/kg/min vs. placebo istaroxime 1.0 ug/kg/min vs. placebo 2 20 5 Infusion period ts fusion period 10 10 & i Placebo - Cohort 2 GER (mL/min/m?) eGFR (mL/min/m?) =~ Placebo Cohort» e taroxime 05 us/Kevmin Oe storoxime 10 ue/Ke/min Baseline 24
Slide 17: Heart Rate was Lowered During Treatment
Heart Rate was Lowered During Treatment Change in Heart Rate (bpm) istaroxime 0.5 yg/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo owann Change in Heart Rate (bpm) == Placebo -Cohort 1 ~@- [staroxime 05 yg/Ke/iin * pvalue= 0.014 ry Tnfusion period @ ££ SF Re eo eos s of ee eH 1saroxne 0 pa
Slide 18: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring Clinically significant arrhythmias Clinically significant arrhythmias 220% 105% 105% 105% 100% 3% 0K 200% 20% _ 60% _ 0% I 40% = eS a sae 20% som 00% 00% Beene ay i(tuser) Day? exzine it Day? lacebo-Cehor 1 misaroimed.s yalkg/min sePlacebo-Co
Slide 19: No Meaningful Increases in Troponin (cTnT) During Treatment
No Meaningful Increases in Troponin (cTnT) During Treatment cInt -0 to24 hours Int -24to 72 hours x0 so 5 6 “ “ s SSS! s== x x» 2s s x» x» 03 6 8 2 as aa me u % & © 7 ActnT—0to24hours AcTnT -24to 72 hours . ‘ os aes 3 2 a i 2 2 o 3 6 9 2 w w nm 2 xs «@ o @ 05 uela/min —e— 1.0 uala/min = 9 = Placebo
Slide 20: Adverse Events
Adverse Events Istaroxime 0.5 istaroxime 1.0 con ca main popaae (n=41) ) All adverse events, 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to pablo 1 (2.6%) : 4 (10.0%) Serious adverse events 2 (5.1%) 2 (4.9%) 6 (15.0%) Cardiac death : - 1 (2.5%) Cardiogenic shock = z 1(25%)* Cardiac fail
Slide 21: Istaroxime Phase 2b Study - Summary
Istaroxime Phase 2b Study - Summary * A 24-hour infusion of istaroxime at doses of 0.5 and 1.0 mg/kg/min was associated with significant improvements in diastolic and systolic cardiac function at 24 hours. * The primary endpoint, E/e’ at 24 hours, was significantly (p<0.05) improved by both doses of
Slide 22: Istaroxime — Acute Heart Failure — Program Status
Istaroxime — Acute Heart Failure — Program Status 1. The Company has worked with top Heart Failure advisors and has had positive engagement and guidance from the FDA v_ The FDA granted Fast Track designation to the program in July 2019 2. The Company plans to transition istaroxime to phase 3-ready a
Slide 23: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway " Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output * Approximately 110,000 pat
Slide 24: Istaroxime — Early Cardiogenic Shock
Istaroxime — Early Cardiogenic Shock = FDA continues to recognize cardiogenic shock as an unmet medical need = FDA has outlined their current regulatory position regarding approval of drugs for shock © Sponsors are not required to show a benefit other than an increase in blood pressure to support ap
Slide 25: Istaroxime SBP Change from Baseline, Phase 2a and 2b Dose Groups
Istaroxime SBP Change from Baseline to 6 or 24 Hours from the Phase 2a and 2b Dose Groups Istaroxime has the potential to improve blood pressure and organ perfusion in patients with AHF 20.0 18.0 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change + S
Slide 26: Rationale for Istaroxime in Early Cardiogenic Shock
Rationale for Istaroxime in Early Cardiogenic Shock = Dose related changes in systolic blood pressure in the phase 2 clinical program suggest a meaningful increase in blood pressure may be achieved in early cardiogenic shock by istaroxime = Improving systolic and diastolic cardiac function without i
Slide 27: Novel Heart Failure Portfolio
Novel Heart Failure Portfolio- é Oral and IV SERCA2a Activators for Chronic & Acute Heart Failure {% y Dual Mechanism SERCA2a Selective SERCA2a Activators Activators = SERCA2a activators with Na*/K* = Selective SERCA2a Activators devoid of pump inhibitory activities any Na*/K* pump inhibitory activi
Slide 28: AEROSURF
AEROSURF*® Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System for the Treatment of RDS
Slide 29: Respiratory Distress Syndrome (RDS)
Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf
Slide 30: Clinicians Seeking a Noninvasive Way to Deliver Surfactant
Clinicians Seeking a Noninvasive Way to Deliver Surfactant What is wanted?: v Avoid the risks, complications and clinical instability associated with delivery of surfactant therapy via intubation and mechanical ventilation Y Possibility of repeat doses v Enable administration by non- specialist staf
Slide 31: Windtree Technology Platform
Windtree Technology Platform - Proprietary Synthetic KL4 Surfactant AEROSURF® Structurally similar to human lung surfactant Liquid KLs surfactant (intratracheal instillate) for RDS approved by the FDA lyophilized KLs surfactant currently being developed for AEROSURF 33 Utilizing pressure and heated
Slide 32: AEROSURF - Potential to Impact on the Clinical Course of RDS
AEROSURF® - Potential to Impact on the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment ® Improved Long-Term AEROSURF Respiratory Outcomes Study results across each Faramieters of these important + parameters show evidence 1 of the potential to impa
Slide 33: AEROSURF Program Evolution and Strategy
AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach Program Evolution = The four phase 2a and 2b clinical trials have reproduced efficacy in reducing nCPAP failure and the need for intubation and observed important positive BPD data. © AEROSURF has received Fast
Slide 34: Rostafuroxin
Rostafuroxin for genetically targeted resistant hypertension and renal impairment SQ winotree
Slide 35: Hypertension Market — A Unique, Genetically-Targeted Approach
Hypertension Market — A Unique, Genetically-Targeted Approach * Hypertension is a very large market with high unmet need * Over 1/3 of the adult population in the U.S. has hypertension and the majority of treated patients (50-85% globally) do not reach target for control. Well known that ethnicity c
Slide 36: Rostafuroxin Next Steps
Rostafuroxin Next Steps 1. Complete pharmaceutical development work for final formulation 2. Continue ongoing work to explain the ethnic differences seen in the Phase 2b clinical trial, including a more sensitive assay to measure drug concentration 3. Seek to develop rostafuroxin into an asset that
Slide 37: Financial Update
Financial Update As of June 30, 2019 = Cash and marketable securities of $6.1 million as of June 30, 2019 * Supports development activities, operations and debt service through October 2019 * The Company is actively engaged in discussions with a number of potential counterparties to secure additiona
Slide 38: Strategy for Value Creation
Strategy for Value Creation Planned Milestones Ista: conduct clinical study of early cardiogenic shock to explore potential accelerated pathway for approval of this indication. Complete ista phase 2 clinical program and develop strong phase 3 and partnership position; to create added value, advance
Slide 39: Windtree Therapeutics
Windtree Therapeutics “Striving to deliver Hope for a Lifetime!” SQ winotree a6
Windtree Therapeutics — Investor Presentation (October 2019) on 6ix